Vadim Gushchin, MD
Dr. Vadim Gushin is an accomplished surgical oncologist who is skilled in robotic surgery as well as the complex HIPEC surgery that combines cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. As Director of the HIPEC Program the Mercy Medical Center in Baltimore, Maryland, where he treats patients diagnosed with malignant peritoneal mesothelioma and other cancers.[1]
Since completing his medical education and training, Dr. Gushchin has provided care for patients and worked to advance medical education and clinical training for others nationally and internationally. In addition to leading Mercy’s Surgical Oncology Fellowship Program, he also serves as Director of the Surgical Oncology continuing medical education program. He is also a leader in addressing global disparities in oncology care and education and founded the Higher School of Oncology in Russia to supplement traditional training with modern oncology concepts.[1]
Professional Memberships and Activities
Dr. Gushchin is an active member of numerous professional organizations, including:[1]
- American College of Surgeons
- Society of Laparoscopic Surgeons
- The Society for Surgery of the Alimentary Tract
- Association for Academic Surgery
- North American Neuroendocrine Tumor Society (NANETS)
Research
Dr. Gushchin takes an active role in clinical studies aimed at improving surgical treatment and long-term patient survival. His recent research includes:
- Building an Efficient Peritoneal Surface Malignancies Program Despite the Lower-Middle-Income Barriers: Ukraine Experience. Kopetskyi V, Antoniv M, Yarema R, Maksymovskyi V, Chetverikova-Ovchinnik V, Kryzhevskyi V, Volodko N, Gushchin V, Nikiforchin. JCO Glob Oncol. 2024 Feb ;10():e2300432. doi: 10.1200/GO.23.00432 PURPOSE: Cytoreductive surgery/hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) programs are often limited to centers in developed countries because of extensive requirements. We aimed to analyze efficacy and challenges of CRS/HIPEC centers in lower-middle-income settings in the Ukraine example. METHODS: A multicenter descriptive study was conducted using data sets (2008-2022) from Kyiv, Lviv, and Odesa centers….
- Collaborative expertise of gynecological and surgical oncologists in managing advanced epithelial ovarian cancer. Nikiforchin A, Sardi A, King MC, Baron E, Lopez-Ramirez F, Falla-Zuniga LF, Barakat P, Iugai S, Pawlikowski K, Nieroda C, Campbell K, Ryu H, Diaz-Montes T, Gushchin. Eur J Surg Oncol. 2024 Feb ;50(2):107948. doi: 10.1016/j.ejso.2023.107948. BACKGROUND: Most patients with epithelial ovarian cancer (EOC) present with significant peritoneal spread. We assessed collaborative efforts of surgical and gynecological oncologists with expertise in cytoreductive surgery (CRS) in the management of advanced EOC. METHODS: Using a prospective single-center database (2014-2022), we described the operative and oncologic outcomes of stage IIIC-IVA primary and recurrent E…
- Sufficient Regional Lymph Node Examination for Staging Adenocarcinoma of the Appendix. Lopez-Ramirez F, Sardi A, King MC, Nikiforchin A, Falla-Zuniga LF, Barakat P, Nieroda C, Gushchin. Ann Surg Oncol. 2024 Mar ;31(3):1773-1782. doi: 10.1245/s10434-023-14683-x. BACKGROUND: The presence of lymph node (LN) metastasis is a known negative prognostic factor in appendix cancer (AC) patients. However, currently the minimum number of LNs required to adequately determine LN negativity is extrapolated from colorectal studies and data specific to AC is lacking. We aimed to define the lowest number of LNs required to adequately stage AC and assess its impact on oncologic outcomes. METH…
- Patterns of Recurrence in Appendix Cancer After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. Nikiforchin A, Sardi A, King MC, Baron E, Lopez-Ramirez F, Falla-Zuniga LF, Barakat P, Iugai S, Pawlikowski K, Nieroda C, Gushchin. Ann Surg Oncol. 2023 Nov ;30(12):7848-7857. doi: 10.1245/s10434-023-14145-4. BACKGROUND: It is thought that low-grade (LG) appendiceal cancer (AC) demonstrates predominantly intraperitoneal recurrence (IPR) after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC), whereas high-grade (HG) tumors progress both intra- and extraperitoneally (EPR). However, evidence supporting this conception is lacking; therefore, we assessed recurrence in various AC histologies. MET…
- Achieving Intraperitoneal Disease Control Using Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Two Cases of Metastatic Breast Cancer. Barakat P, Gushchin V, Falla Zuniga LF, King MC, Sardi. Cureus. 2023 May ;15(5):e38767. pii: e38767. Peritoneal metastases from breast cancer (PMBC) tend to occur late in the disease course and are challenging to manage. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) provide peritoneal disease control in other malignancies and may achieve similar results in PMBC. We assessed intraperitoneal disease control and outcomes in two PMBC patients after CRS/HIPEC. Patient 1, diagnosed at age…
- Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal dissemination from ovarian carcinosarcoma. Lopez-Ramirez F, Sardi A, Studeman K, King MC, Falla-Zuniga LF, Nikiforchin A, Baron E, Nieroda C, Gushchin V, Diaz-Montes. Eur J Surg Oncol. 2023 Aug ;49(8):1495-1503. doi: 10.1016/j.ejso.2023.03.230. BACKGROUND: Ovarian carcinosarcoma (OCS) is an uncommon and aggressive malignancy, with poor response to current treatment approaches and no clear guidelines. Our aim is to evaluate the outcomes of an OCS cohort after cytoreduction with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). METHODS: A descriptive cohort study was performed. Patients who underwent CRS/HIPEC for peritoneal dissemination from tubo-ovari…
